Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active... – Aftertreated polymer
Reexamination Certificate
2004-12-14
2010-06-15
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Solid synthetic organic polymer as designated organic active...
Aftertreated polymer
Reexamination Certificate
active
07736635
ABSTRACT:
Branched molecular scaffolds are provided which are capable of linking two polymer residues (derived, for example, from polyethylene glycol) to two, three or four residues derived from biologically active molecules (e.g. from whole antibodies or from functionally active fragments or derivatives thereof), the latter being attached to the scaffold by means of hydrolytically stable linkages.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5219996 (1993-06-01), Bodner et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5516637 (1996-05-01), Huang et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5677425 (1997-10-01), Bodmer et al.
patent: 5698426 (1997-12-01), Huse
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5750753 (1998-05-01), Kimae et al.
patent: 5780225 (1998-07-01), Wigler et al.
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 6251382 (2001-06-01), Greenwald et al.
patent: 6362254 (2002-03-01), Harris et al.
patent: 2002/0009426 (2002-01-01), Greenwald et al.
patent: 2003/0021790 (2003-01-01), Hsei et al.
patent: 2003/0211078 (2003-11-01), Heavner
patent: 2004/0225097 (2004-11-01), Nho et al.
patent: 1 496 076 (2005-01-01), None
patent: 0 315 450 (1929-07-01), None
patent: 0 315 457 (1929-07-01), None
patent: 0 319 588 (1931-03-01), None
patent: 0 329 825 (1980-05-01), None
patent: WO 90/02809 (1990-03-01), None
patent: WO 91/10737 (1991-07-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/02551 (1992-02-01), None
patent: WO 92/18619 (1992-10-01), None
patent: WO 92/22853 (1992-12-01), None
patent: WO 93/08829 (1993-05-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 95/15982 (1995-06-01), None
patent: WO 95/20401 (1995-08-01), None
patent: WO 98/25971 (1998-06-01), None
patent: WO 02/27315 (2002-04-01), None
patent: WO 03/31475 (2003-04-01), None
patent: WO 2004060965 (2004-07-01), None
patent: WO2005/002870 (2005-01-01), None
patent: WO2005/002871 (2005-01-01), None
patent: WO2005/003169 (2005-01-01), None
patent: WO2005/061005 (2005-07-01), None
Normaln et al, Improved Tumour Targeting with Recombinant Antibody-Macrocycle Conjugates, J. Chem. Soc., Chem. Commun., 1995, 1877-1878.
Ames, R.S., et al., “Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins,” J. Immunol. Methods, 1995, 184, 177-186.
Badcook, J., et al., “A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities,” Proc. Natl. Acad. Sci. USA, 1996, 93, 7843-7848.
Brinkman, U., et al., “Phage display of disulfide-stabilized Fv fragments,” J. Immunol. Methods, 1995, 182, 41-50.
Burton, D.R., et al., “Human antibodies from combinatorial libraries,” Advances in Immunology, 1994, 57, 191-280.
Chapman, A.P., et al., “Therapeutic antibody fragments with prolonged in vivo half-lives,” Nature Biotechnology, 1999, 17(8), 780-783.
Chapman, A.P., “PEGylated antibodies and antibody fragments for improved therapy: a review,”, Advanced Drug Delivery Reviews, 2002, 54, 531-545.
Cole, et al., “The EBV-hybridoma technique and its application to human lung cancer,” Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 1985, 77-96.
Greenwald, R.B., et al., “Highly water soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates,” J. Org. Chem., 1995, 60, 331-336.
Hurwitz, E., et al., “Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies,” Cancer Immunology & Immunotherapy, 2000, 49(4-5), 226-234.
Kettleborough, C.A., et al., “Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments,” Eur. J. Immunol., 1994, 24, 952-958.
Köhler, G., et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, 1975, 256, 495-497.
Kozbor, D., et al., “the production of monoclonal antibodies from human lymphocytes,” Immunology Today, 1983, 4, 72-79.
Mantovani, G., et al., “Design and synthesis of N-maleimido-functionalized hydrophilic polymers via copper mediated living radical polymerization: a suitable alternative to PEGylation chemistry,” J. Am. Chem. Soc., 127(9), 2966-2973, 2005.
Milstein, C., et al., “Hybrid hybridomas and their use in immunohistochemistry,” Nature, 1983, 305, 537-539.
Natarajan, A., et al., “Characterization of site specific ScFv PEGylation for tumor targeting pharmaceuticals,” Bioconjugate Chem., 2005, 16(1), 113-121.
Persic, L., et al., :An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries, Gene, 1997, 187, 9-18.
Tessmar, J., et al., “The use of poly(ethylene glycol)-block-poly(lactic acid) derived copolymers for the rapid creation of biomimetic surfaces,” Biomaterials, 2003, 24(24), 4475-4486.
Traunecker, A., et al., “Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells,” EMBO J., 1991, 10, 3655-3659.
Dickinson Paul
Hartley Michael G
McDonnell Boehnen & Hulbert & Berghoff LLP
UCB Pharma S.A.
LandOfFree
Branched molecular scaffolds for linking polymer residues to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Branched molecular scaffolds for linking polymer residues to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Branched molecular scaffolds for linking polymer residues to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4221059